-
How The Market For Tesaro's Niraparib Plays Out Following Early FDA Approval
Tuesday, March 28, 2017 - 8:46am | 399Read More...TESARO Inc (NASDAQ: TSRO)'s niraparib has received FDA approval, ahead of its Prescription Drug User Fee Act date of June 30. Wedbush’s David M. Nierengarten reiterated an Outperform rating on the company, while raising the price target from $164 to $174. FDA Approval “With firstmover...
-
An Expected Failure From Karyopharm's Selinexor Doesn't Change The Bull Thesis
Friday, March 3, 2017 - 9:27am | 414Read More...Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced that the interim analysis of its Phase 2 SOPRA study of selinexor monotherapy in acute myelogenous leukemia (AML) failed to meet the primary endpoint of overall survival (OS). Wedbush’s David M. Nierengarten maintaisd an Outperform rating...
-
Why A Patient Death Doesn't Necessarily Scuttle Stemline's Chances For SL-401 Approval
Monday, February 6, 2017 - 9:49am | 274Read More...Following Stemline Therapeutics Inc (NASDAQ: STML)'s announcement of the third confirmed capillary leak syndrome related death in the company’s ongoing Phase 2 Blastic Plasmacytoid Dendritic Cell Neoplasm study, Wedbush’s David M. Nierengarten expressed concern regarding a possible FDA...
-
Clovis' Rubraca Vs. TESARO's Niraparib
Tuesday, December 20, 2016 - 10:45am | 356Read More...Clovis Oncology Inc (NASDAQ: CLVS)'s Rubraca (rucaparib) has received accelerated approval from the FDA for monotherapy treatment of advanced ovarian cancer. Despite this head-start, TESARO Inc (NASDAQ: TSRO)'s Niraparib seems to be “the likely winner,” Wedbush’s David M....
-
Wedbush Previews Medivation's Q2 Earnings, Sees Takeout In Mid- To High-$60 Range
Tuesday, July 12, 2016 - 9:01am | 314Read More...Wedbush’s David M. Nierengarten believes that a likely takeout price for Medivation Inc (NASDAQ: MDVN) would be in the mid- to high-$60 per share range, including the probable realized value of any CVR for Talazoparib. Nierengarten reiterated an Outperform rating on the company, while raising...
-
Wedbush Downgrades Infinity Pharma To Underperform, Slashes Target To $3
Tuesday, March 22, 2016 - 1:31pm | 287Read More...Wedbush’s David M. Nierengarten downgraded the rating for Infinity Pharmaceuticals Inc. (NASDAQ: INFI) from Neutral to Underperform, while reducing the price target from $8 to $3. He said that safety concerns related to Zydelig are likely to limit Duvelisib’s opportunity. The FDA...
-
Wedbush Likes Voyager's Gene Therapy Pipeline, Initiates At Outperform
Monday, December 7, 2015 - 10:21am | 393Read More...Shares of Voyager Therapeutics Inc (NASDAQ: VYGR) have appreciated 64.79 percent over the past month, with the share price almost at the 52-week high on December 4. Wedbush’s David M. Nierengarten initiated coverage of the company with an Outperform rating and price target of $36. The...
-
Wedbush Cuts Fibrocell Science To Neutral
Monday, September 28, 2015 - 8:49am | 303Read More...Shares of Fibrocell Science Inc (NASDAQ: FCSC) have risen by more than 97 percent year-to-date, reaching a high of $7.48 on August 5. Wedbush’s David M. Nierengarten has downgraded Fibrocell Science from Outperform to Neutral, while lowering the price target from $7 to $6. The...
-
Wedbush On Anacor Pharma: Crisaborole Delivers, Reiterate Outperform
Monday, July 13, 2015 - 2:33pm | 254Read More...In a report rolled out Monday, Wedbush analysts David M. Nierengarten, Dilip Joseph and Robert Driscoll reiterated an Outperform rating on shares of Anacor Pharmaceuticals Inc (NASDAQ: ANAC), while boosting their price target from $85 to $190. Shares of Anacor were up more than 55 percent on...
-
Bluebird Bio Shares Under Pressure As Wedbush Warns Of Pediatric Study Delay
Wednesday, June 10, 2015 - 12:15pm | 295Read More...A recommended delay in a pediatric trial of Bluebird Bio Inc (NASDAQ: BLUE)'s anemia treatment LentiGlobin won't affect its launch date, an analyst said Tuesday. The biotech company was off nearly 3 percent recently at $181.17 Bluebird said Tuesday that a panel advising the...
-
Wedbush Initiates Blueprint Medicines At Outperform, Calls It A 'Template For Targeted Therapies'
Tuesday, May 26, 2015 - 2:40pm | 386Read More...Wedbush initiated coverage on Blueprint Medicines Corp (NASDAQ: BPMC) Friday with an Outperform rating and $41 price target. Analysts led by David M. Nierengarten felt that the company’s differentiated approach combined “a highly-annotated novel proprietary compound library and...
-
Wedbush Sees More News On Bluebird Bio Coming Thursday
Wednesday, May 20, 2015 - 8:35am | 264Read More...Bluebird Bio Inc. (NASDAQ: BLUE) will see additional "positive news" early Thursday, when abstracts of studies related to its LentiGlobin treatment will be published by the European Hematology Association, an analyst said. Meanwhile, recent talks with U.S. and European regulators...
-
Wedbush Securities Reiterates Outperform, Raises PT On Medivation On Increased International Estimates
Wednesday, March 11, 2015 - 8:22am | 194Read More...In a report published Wednesday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating on Medivation Inc. (NASDAQ: MDVN), and raised the price target from $118.00 to $138.00. In the report, Wedbush Securities noted, "Raising our international Xtandi estimates on global...
-
Wedbush Securities Sees Dose Escalation Trials Continue Without Toxicity Signals For Endocyte
Tuesday, March 3, 2015 - 9:50am | 88Read More...In a report published Tuesday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating and $12.00 price target on Endocyte, Inc. (NASDAQ: ECYT). In the report, Wedbush Securities noted, "ECYT reported a Q4:14 EPS of $(0.19), in line with our $(0.20) estimate and above...
-
Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma
Friday, February 27, 2015 - 11:34am | 123Read More...In a report published Friday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating and $111.00 price target on Synageva Biopharma Corp. (NASDAQ: GEVA). In the report, Wedbush Securities noted, "GEVA reported Q4:14 EPS of ($1.73), slightly below our estimate of ($1.67)...
